The functions of fluoxetine and identification of fluoxetine-mediated circular RNAs and messenger RNAs in cerebral ischemic stroke

References

• Randolph SA. Ischemic stroke. Workplace Health Saf. 2016;64(9):444.
   PubMed Web of Science ®Google Scholar
• Wu S, Yuan R, Wang Y, et al. Early prediction of malignant brain edema after ischemic stroke. Stroke. 2018;49(12):2918–2927. .
   PubMed Web of Science ®Google Scholar
• Saliba E, Debillon T, Auvin S, et al. [Neonatal arterial ischemic stroke: review of the current guidelines]. Arch Pediatr. 2017;24(2):180–188. .
   PubMed Web of Science ®Google Scholar
• Kessner SS, Schlemm E, Cheng B, et al. Somatosensory deficits after ischemic stroke. Stroke. 2019;50(5):1116–1123. .
   PubMed Web of Science ®Google Scholar
• Nave AH, Lange KS, Leonards CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242(2):496–503. .
   PubMed Web of Science ®Google Scholar
• Favate AS, Younger DS. Epidemiology of ischemic stroke. Neurol Clin. 2016;34(4):967–980.
   PubMed Web of Science ®Google Scholar
• Chauhan G, Debette S. Genetic risk factors for ischemic and hemorrhagic stroke. Curr Cardiol Rep. 2016;18(12):124.
   PubMed Web of Science ®Google Scholar
• Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA. Statins in stroke prevention: present and future. Curr Pharm Des. 2016;22(30):4638–4644.
   PubMed Web of Science ®Google Scholar
• Gelbenegger G, Postula M, Pecen L, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Med. 2019;17(1):198. .
   PubMed Web of Science ®Google Scholar
• Marklund M, Wu JHY, Imamura F, et al. Biomarkers of dietary omega-6 fatty acids and incident cardiovascular disease and mortality. Circulation. 2019;139(21):2422–2436. .
   PubMed Web of Science ®Google Scholar
• Perez-Caballero L, Torres-Sanchez S, Bravo L, et al. Fluoxetine: a case history of its discovery and preclinical development. Expert Opin Drug Discov. 2014;9(5):567–578. .
   PubMed Web of Science ®Google Scholar
• Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986;32(6):481–508.
   PubMed Web of Science ®Google Scholar
• Robert A, Schultz IR, Hucher N, et al. Toxicokinetics, disposition and metabolism of fluoxetine in crabs. Chemosphere. 2017;186:958–967.
   PubMed Web of Science ®Google Scholar
• Sun Y, Sun X, Qu H, et al. Neuroplasticity and behavioral effects of fluoxetine after experimental stroke. Restor Neurol Neurosci. 2017;35(5):457–468. .
   PubMed Web of Science ®Google Scholar
• Marwari S, Dawe GS. (R)-fluoxetine enhances cognitive flexibility and hippocampal cell proliferation in mice. J Psychopharmacol. 2018;32(4):441–457.
   PubMed Web of Science ®Google Scholar
• Marcinkute M, Afshinjavid S, Fatokun AA, et al. Fluoxetine selectively induces p53-independent apoptosis in human colorectal cancer cells. Eur J Pharmacol. 2019;857:172441.
   PubMed Web of Science ®Google Scholar
• Alboni S, van Dijk RM, Poggini S, et al. Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment. Mol Psychiatry. 2017;22(4):552–561. .
   PubMed Web of Science ®Google Scholar
• He Y, Cai Z, Zeng S, et al. Effect of fluoxetine on three-year recurrence in acute ischemic stroke: a randomized controlled clinical study. Clin Neurol Neurosurg. 2018;168:1–6.
   PubMed Web of Science ®Google Scholar
• He YT, Tang BS, Cai ZL, et al. Effects of fluoxetine on neural functional prognosis after ischemic stroke: a randomized controlled study in China. J Stroke Cerebrovasc Dis. 2016;25(4):761–770. .
   PubMed Web of Science ®Google Scholar
• Asadollahi M, Ramezani M, Khanmoradi Z, et al. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. Clin Rehabil. 2018;32(8):1069–1075. .
   PubMed Web of Science ®Google Scholar
• Corbett AM, Sieber S, Wyatt N, et al. Increasing neurogenesis with fluoxetine, simvastatin and ascorbic acid leads to functional recovery in ischemic stroke. Recent Pat Drug Deliv Formul. 2015;9(2):158–166. .
   PubMedGoogle Scholar
• Das A, Gorospe M, Panda AC. The coding potential of circRNAs. Aging (Albany NY). 2018;10(9):2228–2229.
   PubMedGoogle Scholar
• Patop IL, Kadener S. CircRNAs in cancer. Curr Opin Genet Dev. 2018;48:121–127.
   PubMed Web of Science ®Google Scholar
• Li LJ, Leng RX, Fan YG, et al. Translation of noncoding RNAs: focus on lncRNAs, pri-miRNAs, and circRNAs. Exp Cell Res. 2017;361(1):1–8. .
   PubMed Web of Science ®Google Scholar
• Holdt LM, Kohlmaier A, Teupser D. Molecular functions and specific roles of circRNAs in the cardiovascular system. Noncoding RNA Res. 2018;3(2):75–98.
   PubMedGoogle Scholar
• Altesha MA, Ni T, Khan A, et al. Circular RNA in cardiovascular disease. J Cell Physiol. 2019;234(5):5588–5600. .
   PubMed Web of Science ®Google Scholar
• Floris G, Zhang L, Follesa P, et al. Regulatory role of circular RNAs and neurological disorders. Mol Neurobiol. 2017;54(7):5156–5165. .
   PubMed Web of Science ®Google Scholar
• Lu S, Yang X, Wang C, et al. Current status and potential role of circular RNAs in neurological disorders. J Neurochem. 2019;150(3):237–248. .
   PubMed Web of Science ®Google Scholar
• Arnaiz E, Sole C, Manterola L, et al. CircRNAs and cancer: biomarkers and master regulators. Semin Cancer Biol. 2019;58:90–99.
   PubMed Web of Science ®Google Scholar
• Xia X, Tang X, Wang S. Roles of circRNAs in autoimmune diseases. Front Immunol. 2019;10:639.
   PubMed Web of Science ®Google Scholar
• Yang J, Chen M, Cao RY, et al. The role of circular RNAs in cerebral ischemic diseases: ischemic stroke and cerebral ischemia/reperfusion injury. Adv Exp Med Biol. 2018;1087:309–325.
   PubMed Web of Science ®Google Scholar
• Yang X, Ji H, Yao Y, et al. Downregulation of circ_008018 protects against cerebral ischemia–reperfusion injury by targeting miR-99a. Biochem Biophys Res Commun. 2018;499(4):758–764. .
   PubMed Web of Science ®Google Scholar
• Cui J, Zhou B, Ross SA, et al. Nutrition, microRNAs, and human health. Adv Nutr. 2017;8(1):105–112. .
   PubMed Web of Science ®Google Scholar
• Zhao S, Yan L, Zhao Z, et al. Up-regulation of miR-203 inhibits the growth of cervical cancer cells by inducing cell cycle arrest and apoptosis. Eur J Gynaecol Oncol. 2019;40(5):791–795.
   Web of Science ®Google Scholar
• Liu W, Miao Y, Zhang L, et al. MiR-211 protects cerebral ischemia/reperfusion injury by inhibiting cell apoptosis. Bioengineered. 2020;11(1):189–200. .
   PubMed Web of Science ®Google Scholar
• Jiao H, Chen R, Jiang Z, et al. MiR-22 protect PC12 from ischemia/reperfusion-induced injury by targeting p53 upregulated modulator of apoptosis (PUMA). Bioengineered. 2020;11(1):209–218. .
   PubMed Web of Science ®Google Scholar
• Zhong Y, Du Y, Yang X, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17(1):79. .
   PubMed Web of Science ®Google Scholar
• Li Y, Huo C, Lin X, et al. Computational identification of cross-talking ceRNAs. Adv Exp Med Biol. 2018;1094:97–108.
   PubMed Web of Science ®Google Scholar
• Qian L, Yu S, Chen Z, et al. The emerging role of circRNAs and their clinical significance in human cancers. Biochim Biophys Acta Rev Cancer. 2018;1870(2):247–260. .
   PubMed Web of Science ®Google Scholar
• Li X, Yang L, Chen -L-L. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–442.
   PubMed Web of Science ®Google Scholar
• Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91. .
   PubMed Web of Science ®Google Scholar
• Li M, Zhao L, Li S, et al. Differentially expressed lncRNAs and mRNAs identified by NGS analysis in colorectal cancer patients. Cancer Med. 2018;7(9):4650–4664. .
   PubMed Web of Science ®Google Scholar
• Wang Z, Shang P, Li Q, et al. ITRAQ-based proteomic analysis reveals key proteins affecting muscle growth and lipid deposition in pigs. Sci Rep. 2017;7:46717.
   PubMed Web of Science ®Google Scholar
• Zhou C, He Y, Li X. Cerebral achromatopsia secondary to ischemic stroke. Neurol India. 2018;66(2):573–575.
   PubMed Web of Science ®Google Scholar
• Heneghan C, Mahtani KR. Routine fluoxetine in stroke. BMJ Evid Based Med. 2019;24(5):195–196.
   PubMedGoogle Scholar
• van der Worp HB. Fluoxetine and recovery after stroke. Lancet. 2019;393(10168):206–207.
   PubMed Web of Science ®Google Scholar
• Hancu G, Carcu-Dobrin M, Budau M, et al. Analytical methodologies for the stereoselective determination of fluoxetine: an overview. Biomed Chromatogr. 2018;32:1.
   Web of Science ®Google Scholar
• Pham VT, Nguyen TQ, Dao UPN, et al. On the interaction between fluoxetine and lipid membranes: effect of the lipid composition. Spectrochim Acta A Mol Biomol Spectrosc. 2018;191:50–61.
   PubMed Web of Science ®Google Scholar
• Wang G, Han B, Shen L, et al. Silencing of circular RNA HIPK2 in neural stem cells enhances functional recovery following ischaemic stroke. EBioMedicine. 2020;52:102660.
   PubMed Web of Science ®Google Scholar
• Peng X, Jing P, Chen J, et al. The role of circular RNA HECTD1 expression in disease risk, disease severity, inflammation, and recurrence of acute ischemic stroke. J Clin Lab Anal. 2019;33(7):e22954. .
   PubMed Web of Science ®Google Scholar
• Han B, Zhang Y, Zhang Y, et al. Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke. Autophagy. 2018;14(7):1164–1184. .
   PubMed Web of Science ®Google Scholar
• Bai Y, Zhang Y, Han B, et al. Circular RNA DLGAP4 ameliorates ischemic stroke outcomes by targeting miR-143 to regulate endothelial-mesenchymal transition associated with blood-brain barrier integrity. J Neurosci. 2018;38(1):32–50. .
   PubMed Web of Science ®Google Scholar
• Wu F, Han B, Wu S, et al. Circular RNA TLK1 aggravates neuronal injury and neurological deficits after ischemic stroke via miR-335-3p/TIPARP. J Neurosci. 2019;39(37):7369–7393. .
   PubMed Web of Science ®Google Scholar
• Chen Z, Gao Y, Gao S, et al. MiR-135b-5p promotes viability, proliferation, migration and invasion of gastric cancer cells by targeting Krüppel-like factor 4 (KLF4). Arch Med Sci. 2020;16(1):167–176. .
   PubMed Web of Science ®Google Scholar
• Duan Q, Sun W, Yuan H, et al. MicroRNA-135b-5p prevents oxygen-glucose deprivation and reoxygenation-induced neuronal injury through regulation of the GSK-3β/Nrf2/ARE signaling pathway. Arch Med Sci. 2018;14(4):735–744. .
   PubMed Web of Science ®Google Scholar
• Di Pietro V, Porto E, Ragusa M, et al. Salivary microRNAs: diagnostic markers of mild traumatic brain injury in contact-sport. Front Mol Neurosci. 2018;11:290.
   PubMed Web of Science ®Google Scholar
• Yang N, Gao X, Qu X, et al. PIDD mediates radiation-induced microglia activation. Radiat Res. 2016;186(4):345–359. .
   PubMed Web of Science ®Google Scholar
• Bock FJ, Krumschnabel G, Manzl C, et al. Loss of PIDD limits NF-κB activation and cytokine production but not cell survival or transformation after DNA damage. Cell Death Differ. 2013;20(4):546–557. .
   PubMed Web of Science ®Google Scholar